Patient-Reported Outcomes With Amivantamab/Lazertinib

The Paloma-3 study provided important insights into patient-reported outcomes with the subcutaneous formulation of amivantamab. Historically, cancer treatment focused primarily on clinical efficacy, often at the expense of tolerability and patient comfort. However, there has been a meaningful shift in recent years toward valuing how patients feel during treatment, not just how well the drugs perform in terms of survival or disease control. Paloma-3 highlighted that patients receiving subcutaneous amivantamab experienced improved quality of life, with reduced treatment burden and fewer adverse effects interfering with daily activities.

This evolving emphasis on patient-centered care aligns with the broader changes in oncology, where the patient experience is increasingly seen as a critical metric of treatment success. Subcutaneous administration not only shortens clinic time but also minimizes the physical and emotional toll of therapy. When paired with strategies like those studied in the Cocoon trial—prophylactic management of common adverse effects such as rash and skin irritation—the overall treatment experience is further improved. These interventions make it easier for patients to stay on therapy, leading to better adherence and potentially better outcomes.

Altogether, these developments mark a significant shift in the approach to cancer care—prioritizing not only survival but also the quality of that survival. The combination of subcutaneous delivery and proactive supportive care enhances convenience and tolerability. As newer therapies continue to emerge, this focus on patient-reported outcomes ensures that treatments are not only effective but also manageable, reinforcing the importance of listening to and partnering with patients throughout their treatment journey.